Drug recall · December 18, 2024
Levothyroxine Sodium Tablets recall
Why: Subpotent and Superpotent Drug
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-040-20
- Lots / codes
Lot #: 3115869, Exp. Date 03/2025
- Quantity
- 205 cartons
- Company
- Mylan Institutional, Inc., Rockford, IL
- Distribution
- Nationwide in the USA.
- Initiated
- November 19, 2024 · Voluntary: Firm initiated
- Classified
- December 12, 2024
- Reported
- December 18, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Levothyroxine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.